CPMV on OTC
Mosaic ImmunoEngineering Inc.
American biological products company, incorporated in Delaware. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerCPMV on OTC1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersHuntington Beach, California1
- Incorporated inDE2
- Business address9114 Adams Ave., #202, Huntington Beach, Ca 926462
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
Split. On December 30, 2020, we changed our fiscal year end from May 31 to December 31.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $64.0K | $183.9K |
| General and administrative | $552.1K | $695.8K |
| Total operating expenses | $616.1K | $879.7K |
| Loss from operations | -$616.1K | -$879.7K |
| Other income | $14.0K | $42.0K |
| Interest income | $6 | $5 |
| Interest expense on loan payable | -$10.0K | -$7.0K |
| Non-cash interest expense on convertible notes | -$73.3K | -$73.5K |
| Accretion to redemption value on convertible notes | $0 | -$1.4K |
| Total other income, net | -$69.3K | -$39.9K |
| Loss before provision for income taxes | -$685.4K | -$919.6K |
| Provision for income taxes | $2.4K | $2.4K |
| Net loss | -$687.8K | -$922.0K |
| Basic loss per common share | -$0.10 | -$0.13 |
| Diluted loss per common share | -$0.10 | -$0.13 |
| Weighted average number of common shares outstanding basic | 7.2M shares | 7.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $3.6K | $115.0K | |
| Prepaid expenses and other current assets | $16.3K | $26.6K | |
| Total current assets | $19.9K | $141.6K | |
| Total assets | $19.9K | $141.6K | |
| Accounts payable | $132.8K | $134.9K | |
| Accrued compensation | $4.3M | $3.8M | |
| Accrued consulting | $787.9K | $787.9K | |
| Accrued expenses and other | $655.2K | $646.9K | |
| Loan payable | $200.0K | $200.0K | |
| Total current liabilities | $6.0M | $5.5M | |
| Convertible notes, net | $1.5M | $1.4M | |
| Total liabilities | $7.5M | $6.9M | |
| Common stock, $0.00001 par value: 100,000,000 shares authorized: 7,242,137 shares issued and outstanding | $72 | $72 | |
| Additional paid-in capital | $2.1M | $2.1M | |
| Accumulated deficit | -$9.5M | -$8.8M | |
| Total stockholders deficit | -$7.5M | -$6.8M | -$5.9M |
| Total liabilities and stockholders deficit | $19.9K | $141.6K | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares designated | 5.0M shares | 5.0M shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 7.2M shares | 7.2M shares | |
| Common stock, shares outstanding | 7.2M shares | 7.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $3.6K | $115.0K | |
| Prepaid expenses and other current assets | $16.3K | $26.6K | |
| Total current assets | $19.9K | $141.6K | |
| Total assets | $19.9K | $141.6K | |
| Accounts payable | $132.8K | $134.9K | |
| Accrued compensation | $4.3M | $3.8M | |
| Accrued consulting | $787.9K | $787.9K | |
| Accrued expenses and other | $655.2K | $646.9K | |
| Loan payable | $200.0K | $200.0K | |
| Total current liabilities | $6.0M | $5.5M | |
| Convertible notes, net | $1.5M | $1.4M | |
| Total liabilities | $7.5M | $6.9M | |
| Common stock, $0.00001 par value: 100,000,000 shares authorized: 7,242,137 shares issued and outstanding | $72 | $72 | |
| Additional paid-in capital | $2.1M | $2.1M | |
| Accumulated deficit | -$9.5M | -$8.8M | |
| Total stockholders deficit | -$7.5M | -$6.8M | -$5.9M |
| Total liabilities and stockholders deficit | $19.9K | $141.6K | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares designated | 5.0M shares | 5.0M shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 100.0M shares | 100.0M shares | |
| Common stock, shares issued | 7.2M shares | 7.2M shares | |
| Common stock, shares outstanding | 7.2M shares | 7.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$687.8K | -$922.0K |
| Share-based compensation | $0 | $4.9K |
| Non-cash interest on convertible notes | $73.3K | $73.5K |
| Accretion to redemption value on convertible notes | $0 | $1.4K |
| Prepaid expenses and other current assets | $10.3K | -$3.2K |
| Accounts payable | -$2.1K | -$16.4K |
| Accrued compensation | $486.6K | $582.7K |
| Accrued expenses and other | $8.3K | $5.1K |
| Net cash used in operating activities | -$111.4K | -$241.2K |
| Proceeds from the issuance of loans payable | $0 | $270.0K |
| Payments on loan payables | $0 | -$70.0K |
| Net cash provided by financing activities | $0 | $200.0K |
| Net change in cash and cash equivalents | -$111.4K | -$41.2K |
| Cash paid for income taxes | $2.4K | $2.4K |
| Cash paid for interest on loan payable | $0 | $6.2K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Mosaic ImmunoEngineering Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
2010201520202025
- Chief executive officerClifford L. Flowers Jun 7, 2010 to Jun 6, 201313
- Chief executive officerFrederick C. Goerner Mar 12, 2008 to Nov 24, 200814
- Chief executive officerDavid Pohl Apr 17, 2006 to Feb 16, 200715
- Chief financial officerPaul J. Lytle Aug 31, 2020 to Jan 29, 202116
- Chief financial officerClifford L. Flowers Sep 17, 2007 to May 6, 201517
- Chief financial officerThomas J. Sweeney May 31, 2006 to Aug 21, 200718
Board members and other officers (15)
- Chief Scientific OfficerNicole Franziska Steinmetz Aug 31, 2020 to Jan 29, 202119
- VP, Business DevelopmentPaul R. Bibeau Mar 18, 2008 to Apr 15, 200920
- Board memberRobert Baffi Jul 16, 2021 to Feb 22, 202221
- Board memberNicole Franziska Steinmetz Aug 31, 2020 to Feb 22, 202219
- Board memberPaul J. Lytle Aug 31, 2020 to Jan 29, 202116
- Board memberRobert L. Garnick Aug 31, 2020 to Feb 22, 202222
- Board memberDharmesh Mistry Dec 7, 2009 to Dec 7, 200923
- Board memberDonald E. Schrock Apr 24, 2008 to Apr 25, 200824
- Board memberCarlton M. Johnson Nov 21, 2008 to Dec 16, 202025
- Board memberHarry L. Tredennick Aug 28, 2007 to Nov 24, 200826
- Board memberLowell Giffhorn Jan 26, 2006 to Mar 27, 200627
- Board memberDavid Pohl Apr 17, 2006 to Aug 30, 200715
- Board memberGloria Felcyn May 30, 2006 to Feb 22, 202228
- Board memberHelmut Falk Jr. May 30, 2006 to Dec 14, 200929
- Board memberThomas J. Sweeney May 31, 2006 to May 31, 200630
Former names
- PATRIOT SCIENTIFIC CORPDec 11, 1995 to Nov 19, 20202
Timeline
Filings
47 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 12 major events, 5 insider forms, 10 other. The latest 20:
- Aug 14, 202610-Q FORM 10-Q FOR JUN 2026 EDGAR
- May 20, 202610-Q FORM 10-Q FOR MAR 2026 EDGAR
- May 15, 2026NT 10-Q 10-Q EXTENSION FOR MARCH 2026 EDGAR
- Apr 15, 202610-K FORM 10-K FOR DEC 2025 EDGAR
- Mar 31, 2026NT 10-K NOTICE OF LATE FILING EDGAR
- Nov 19, 202510-Q FORM 10-Q FOR SEPT 2025 EDGAR
- Nov 12, 2025NT 10-Q EXTENSION EDGAR
- Aug 19, 202510-Q FORM 10-Q FOR JUNE 2025 EDGAR
- Aug 12, 2025NT 10-Q EXTENSION EDGAR
- May 20, 202510-Q FORM 10-Q FOR MAR 2025 EDGAR
- May 15, 2025NT 10-Q EXTENSION EDGAR
- Apr 15, 202510-K FORM 10-K FOR DEC 2024 EDGAR
- Mar 28, 2025NT 10-K EXTENSION FOR 10-K 2024 EDGAR
- Jan 2, 20258-K EDGAR
- Nov 19, 202410-Q FORM 10-Q FOR SEPT 2024 EDGAR
- Nov 13, 2024NT 10-Q 10-Q EXTENSION EDGAR
- Aug 14, 202410-Q FORM 10-Q FOR JUNE 2024 EDGAR
- Jul 25, 20248-K EDGAR
- May 31, 20248-K EDGAR
- May 21, 20248-K EDGAR
The 47 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARDavid Pohl, Chief executive officer
- 16
- 17
- 18
- 19
- 20
- 21SEC EDGARRobert Baffi, Board member
- 22SEC EDGARRobert L. Garnick, Board member
- 23SEC EDGARDharmesh Mistry, Board member
- 24SEC EDGARDonald E. Schrock, Board member
- 25SEC EDGARCarlton M. Johnson, Board member
- 26SEC EDGARHarry L. Tredennick, Board member
- 27SEC EDGARLowell Giffhorn, Board member
- 28SEC EDGARGloria Felcyn, Board member
- 29SEC EDGARHelmut Falk Jr., Board member
- 30SEC EDGARThomas J. Sweeney, Board member